🍪 Cookies

We use cookies to store, access and process personal data to give you the best online experience. By clicking Accept Cookies you consent to storing all cookies and ensure best website performance. You can modify cookie preferences or withdraw consent by clicking Cookie Settings. To find out more about cookies and purposes, read our Cookie Policy and Privacy Notice.

Cookies settings

Cookie Control

What are cookies?

Cookies are small text files that enable us, and our service provides to uniquely identify your browser or device. Cookies normally work by assigning a unique number to your device and are stored on your browser by the websites that you visit as well as third-party service providers for those website. By the term cookies other technologies as SDKs, pixels and local storage are to be considered.

If Enabled

We may recognize you as a customer which enables customized services, content and advertising, services effectiveness and device recognition for enhanced security
We may improve your experience based on your previous session
We can keep track of your preferences and personalize services
We can improve the performance of Website.

If Disabled

We won't be able to remember your previous sessions, that won't allow us to tailor the website according to your preferences
Some features might not be available and user experience reduced without cookies

Strictly necessary means that essential functions of the Website can not be provided without using them. Because these cookies are essential for the properly working and secure of Website features and services, you cannot opt-out of using these technologies. You can still block them within your browser, but it might cause the disfunction of basic website features.

  • Setting privacy preferences
  • Secure log in
  • Secure connection during the usage of services
  • Filling forms

Analytics and performance tracking technologies to analyze how you use the Website.

  • Most viewed pages
  • Interaction with content
  • Error analysis
  • Testing and Measuring various design effectivity

The Website may use third-party advertising and marketing technologies.

  • Promote our services on other platforms and websites
  • Measure the effectiveness of our campaigns

Your retention will contact you in a few minutes with more information about this trading strategy.

{{ requiredField }}

{{ validEmail }}

{{ item.name }}
{{ item.dial_code }}

{{ validPhone }}

Your message was sent
Too many tries. Try in 2 minutes
locked content icon
This content is locked
to unlock it
return icon

Moderna Poised to Make $ 10 Billion on Covid Booster

With the flu season upon us, the makers of Covid vaccines are back in the headlines as the world looks to contain the new virus mutations. Even before Covid, vaccine development is a very competitive game with companies battling it out with pricing and for market share. The same holds true for vaccines that are considered to be the best against Covid and its mutations, like Pfizer and Moderna.

About the company

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded in 2010 and is headquartered in Cambridge, USA.


Strong advantages

Moderna, along with its main competitor, Pfizer, which makes its shot in collaboration with Germany's BioNTech, still see a major role for themselves in the (Covid) vaccine market even as overall demand declines. Moderna, as well as its competitor brings one key advantage top the table: its vaccine is based on messenger RNA (mRNA) and can be updated somewhat quicker than those from other competitors. Moderna can apply this advantage when developing vaccines targeting the Omicron variant of the Covid virus.

Additionally, the vaccine from Moderna is considered safer for older adults. A possible reason is that the Moderna dose is much higher with 100 μg. Older bodies may need the bigger kick from the larger Moderna dose to prime their immune systems. For persons aged 18-49, there were almost no deaths among two-dose vaccinees.


Key markets

Moderna executives recently said those who would benefit from annual boosting include people over 50 and adults with other health risk factors or high-risk occupations, including healthcare workers. Moderna CEO Stephane Bancel estimated this population to be around 1.7 billion people, or some 21% of the global population.

The company believes that in the coming year, most COVID vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world. It is not known yet how many booster doses will be needed. Second booster shots are currently recommended in some countries for only a subset of the population.


The projected revenue

The United States and Western Europe - where about 600 million people are vaccinated - will remain important markets for the vaccine maker, but sales may be a fraction of what they have been.

This is because most people who wanted to get vaccinated against COVID have already done so - more than 5 billion people worldwide.

That said, shares of COVID-19 vaccine makers including Moderna (MRNA) and Novavax (NVAX) surged after a report that the Biden administration plans to urge Americans to get booster shots for the fall, as new subvariants emerge and cases rise.

For 2023, analysts have forecast global revenue of over $17 billion for Moderna’s main competitor, the Pfizer/BioNTech shot and $10 billion for Moderna's. [1] Sales are expected to drop further from there. It is also unclear if vaccine makers will sell a redesigned shot this fall and each fall afterward, as flu vaccine makers do to match circulating strains, and what impact that might have on waning demand.

Snímek obrazovky 2023-10-06 v 13.31.07

Moderna stock price in a 5-year timeframe. Source: Tradingview.com *


Adam Austera, chief analyst of Ozios

* Past performance is no guarantee of future results.

[1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or based on the current economic environment which is subject to change. Such statements are not guaranteeing of future performance. They involve risks and other uncertainties which are difficult to predict. Results could differ materially from those expressed or implied in any forward-looking statements.


The material herein is considered as marketing communication under the relevant laws and regulations, and as such is not a subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and should not be construed as containing investment advice, or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. The published content is intended for educational/informational purposes only. It does not take into account readers’ financial situation, personal experience or investment objectives. APME FX Trading Europe Ltd makes no representation that the information provided is accurate, current or complete; and therefore, assumes no liability for any losses arising from investments based on the supplied content. The past performance is not a guarantee of future results.

Toyota sells companies to make more EVs

With the flu season upon us, the makers of Covid vaccines are back in the headlines as the world looks to contain the new virus mutations. Even before Covid, vaccine...

Meta Platforms and restrictions in the EU

With the flu season upon us, the makers of Covid vaccines are back in the headlines as the world looks to contain the new virus mutations. Even before Covid, vaccine...

Snapchat deal with Amazon

With the flu season upon us, the makers of Covid vaccines are back in the headlines as the world looks to contain the new virus mutations. Even before Covid, vaccine...
We are also available at +357 25 054 734

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 73.03% of retail investor' accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Read our Risk Disclosures.